Home  /  Resource Library  /  ZANUBRUTINIB (ZANU) VERSUS BENDAMUSTINE + RITUXIMAB (BR) IN PATIENTS (PTS) WITH TREATMENT-NAIVE (TN) CLL/SLL: EXTENDED FOLLOW-UP OF THE SEQUOIA STUDY

ZANUBRUTINIB (ZANU) VERSUS BENDAMUSTINE + RITUXIMAB (BR) IN PATIENTS (PTS) WITH TREATMENT-NAIVE (TN) CLL/SLL: EXTENDED FOLLOW-UP OF THE SEQUOIA STUDY

ICML 2023